Vaptans and the Treatment of Water-Retaining Disorders

Seminars in Nephrology

Volumn 26, Issue 3, 2006, Pages 234-243

  Quittnat, Friedericke ^a   Gross, Peter ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

cardiac failure; hyponatremia; syndrome of inappropriate antidiuretic hormone (SIADH); vaptans; vasopressin

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; COMPLEMENTARY DNA; CONIVAPTAN; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; OPC 21268 A; SATAVAPTAN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; COMPARATIVE STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG CLEARANCE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; HEART FAILURE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KALIURESIS; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PRIORITY JOURNAL; SODIUM URINE LEVEL; TACHYPHYLAXIS; URINE OSMOLALITY; URINE VOLUME; WATER RETENTION;

BENZAZEPINES; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; VASOPRESSINS; WATER;

EID: 33646499848     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.02.003     Document Type: Article

References (55)

1. Gross P., Pehrisch H., Rascher W., et al. Pathogenesis of clinical hyponatremia. Observations of vasopressin and fluid intake in 100 hyponatremic medical patients. Eur J Clin Invest 17 (1987) 123-129
2. Hoorn E.J., Lindemans J., and Zietse R. Development of severe hyponatremia in hospitalized patients. Treatment-related risk factors and inadequate management. Nephrol Dial Transplant 21 (2006) 70-76
3. Musch W., Xhaet O., Hedeshi A., et al. Fall is a frequent motif of admission in patients with chronic hyponatremia. J Am Soc Nephrol 14 (2003) 748A (abstr)
4. Renneboog B., Vandemergel X., Manto M., et al. Is asymptomatic hyponatremia a myth?. J Am Soc Nephrol 14 (2003) 746A (abstr)
5. Arieff A.I. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 314 (1986) 1529-1534
6. Robertson G.L., Mahr E.A., Athar S., et al. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 52 (1973) 2340-2352
7. Leaf A., and Mamby A.R. An antidiuretic mechanism not regulated by extracellular fluid tonicity. J Clin Invest 31 (1952) 60-71
8. Weston R.E., Grossman J., Borun E.R., et al. The pathogenesis and treatment of hyponatremia in congestive heart failure. Am J Med 25 (1958) 558-572
9. Gross P.A., and Anderson R.J. Effects of DDAVP and AVP on sodium and water balance in conscious rat. Am J Physiol 243 (1982) R512-R519
10. Verbalis J.G. An experimental model of syndrome of inappropriate antidiuretic hormone secretion in the rat. Am J Physiol 247 (1984) E540-E553
11. Anderson R.J., Cadnapaphornchai P., Harbottle J., et al. Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion. J Clin Invest 54 (1974) 1473-1479
12. Linas S.L., Anderson R.J., Guggenheim S.J., et al. Role of vasopressin in impaired water excretion in conscious rats with experimental cirrhosis. Kidney Int 20 (1981) 173-180
13. Yaron M., and Bennett C.M. Mechanism of impaired water excretion in acute right ventricular failure in conscious dogs. Circ Res 42 (1978) 801-805
14. Mandell I.N., De Fronzo R.A., Robertson G.L., et al. Role of plasma arginine vasopressin in the impaired water diuresis of isolated glucocorticoid deficiency in the rat. Kidney Int 17 (1980) 186-195
15. Boykin J., De Torrente A., Robertson G.L., et al. Persistent plasma vasopressin levels in the hypoosmolar state associated with mineralocorticoid deficiency. Miner Electrolyte Metab 2 (1979) 310-315
16. Flear C.T.G., and Hilton P. Hyponatremia and severity and outcome of myocardial infarction. Br Med J 1 (1979) 1242-1246
17. Bichet D., Szatalowicz V., Chaimovitz C., et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 96 (1982) 413-417
18. Usberti M., Federico S., Meccariello S., et al. Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int 25 (1984) 422-429
19. Skowsky W.R., and Kikuchi T.A. The role of vasopressin in the impaired water excretion of myxedema. Am J Med 64 (1978) 613-621
20. Schrier R.W., and Berl T. Nonosmolar factors affecting renal water excretion. N Engl J Med 292 (1975) 81-87 141-
21. Rossi N.F. The mechanisms of K-opioid agonist-induced water diuresis. Central vs. peripheral actions. In: Saito T., Kurokawa K., and Yoshida S. (Eds). Neurohypophysis, Recent Progress of Vasopressin and Oxytocin Research (1995), Elsevier, Amsterdam 289-299
22. Manning M., and Sawyer W.H. Development of selective agonists and antagonists of vasopressin and oxytocin. In: Schrier R.W. (Ed). Vasopressin (1985), Raven Press, New York 131-144
23. Burnier M., Waeber B., Nussberger J., et al. Cardiovascular effects of vascular antagonists (V1) to the action of vasopressin in health and diseases. In: Cowley A.W., Liard J.F., and Ausiello D.A. (Eds). Vasopressin, Cellular and Integrative Functions (1988), Raven Press, New York 473-480
24. Oksche A., Leder G., Valet S., et al. Variant amino acids in the extracellular loops of murine and human vasopressin V2 receptors account for differences in cell surface expression and ligand affinity. Mol Endocrinol 16 (2002) 799-813
25. Adrogué H.J., and Madias N.E. Hyponatremia. N Engl J Med 342 (2000) 1581-1589
26. Singer I., and Rotenberg D. Mechanisms of lithium action. N Engl J Med 289 (1973) 254-260
27. Decaux G., Brimioulle S., Genette F., et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med 69 (1980) 99-106
28. Hantman D., Rossier B., Zohlman R., et al. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Ann Intern Med 78 (1973) 870-876
29. Jard S. Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int 34 (1988) S38-S42
30. Michell R.H., Kirk C.J., and Billah M.M. Hormonal stimulation of phophatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 7 (1979) 861-865
31. Thibonnier M., Colos P., Thibonnier A., et al. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 41 (2001) 175-202
32. 2 receptor in rat kidney. J Clin Invest 94 (1994) 1778-1783
33. 2 vasopressin receptor. J Biol Chem 272 (1997) 2486-2492
34. 2 vasopressin receptor by a plasma membrane metalloproteinase. J Biol Chem 270 (1995) 6476-6481
35. Sadeghi H.M., Innamorati G., and Birnbaumer M. Functional properties of mutant V 2 receptors. In: Saito T., Kurokawa K., and Yoshida S. (Eds). Neurhypophysis, Recent Progress of Vasopressin and Oxytocin Research (1995), Elsevier, Amsterdam 445-451
36. Fujiwara T.M., and Bichet D.G. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 16 (2005) 2836-2846
37. 2 receptor antagonist. Br J Pharmacol 105 (1992) 787-791
38. Fujisawa G., Ishikawa S.-E., Tsuboi Y., et al. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 44 (1993) 19-23
39. Saito T., Fujita N., Fujisawa G., et al. Correction of water retention due to vasopressin excess by nonpeptide vasopressin antagonists. In: Saito T., Kurokawa K., and Yoshida S. (Eds). Neurohypophysis. Recent Progress of Vasopressin and Oxytocin Research (1995), Elsevier, Amsterdam 635-642
40. Ohnishi A., Orita Y., Okahara R., et al. Potent aquaretic agent. J Clin Invest 92 (1993) 2653-2659
41. 2 receptor antagonist. In: Zingg H.H., Bourque C.W., and Bichet D.G. (Eds). Vasopressin and Oxytocin; Molecular, Cellular and Clinical Advances (1998), Raven Press, New York 439-443
42. Gross P., Decaux G., Gerbes A.L., et al. Double blind, placebo-controlled study of the activity and tolerance of two doses of VPA-985 in patients with hyponatremia. J Am Soc Nephrol 10 (1999) 121A (abstr)
43. Gerbes A.L., Gülberg V., Ginès P., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist. a randomized double-blind multicenter trial. Gastroenterology 124 (2003) 933-939
44. Tahara A., Tomura Y., Wada K., et al. Pharmacological profile of YM 087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282 (1997) 301-306
45. 2 receptor antagonist (YM 087) in the rat. Eur J Pharmacol 381 (1999) 23-30
46. 2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 55 (1997) 633-637
47. 2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure. J Am Soc Nephrol 16 (2005) 43A (abstr)
48. 2 receptor antagonist. J Clin Invest 98 (1996) 2729-2738
49. Soupart A., Gross P., Legros J.J., et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion in with SR 121 463 B, an orally active, nonpeptide, vasopressin V-2 receptor antagonist. J Am Soc Nephrol 15 (2004) 563A (abstr)
50. 2-receptor antagonist. Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287 (1998) 860-867
51. 2-receptor antagonist OPC 41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292 (2000) 288-294
52. Monillac B., Chini B., Balestre M.N., et al. The binding site of nonpeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem 270 (1995) 25771-25777
53. Esnouf R.M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr D Biol Crytallogr 55 (1999) 938-940
54. Merritt E.A., and Murphy M.E. Raster3D version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr D Biol Crytallogr 50 (1994) 869-873
55. Macion-Dazard R., Callahan N., Xu Z., et al. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther 316 (2006) 564-571